Gm-Csf
Cancer of Liver
Lisa H. Butterfield, Ph.D.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
3 Active assets in the Cancer of Liver cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Bxcl501 Uppsala University Hospital | Phase 4 | BBB |
Rapamycin University of Chicago | Phase 1 | CCC |
Amsulostat University of Rochester | Phase 1/2 | CCC |
PREDNISONE TABLETS Leaf Vertical Inc. | Phase 1/2 | CCC |
Bortezomib Leaf Vertical Inc. | Phase 1/2 | CCC |
Metformin University of Chicago | Phase 1 | CC |
Catequentinib IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A | D |
HEPARIN H. Lee Moffitt Cancer Center and Research Institute | N/A | D |
Same molecule, other indications
Gm-Csf is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →